Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Across the market, sales exceeded the same period of the previous fiscal year, driven by growth in new drugs and other factors, with sales of anticancer drugs and specialty pharmaceuticals increasing. Meanwhile, profit declined due to lower demand for products related to COVID-19, higher procurement costs for pharmaceuticals, a decline in the number of prescriptions filled due to an increase in long-term prescriptions, delays in the launch of certain contract products, and surging material and raw material costs.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥808,544 million (YoY +5.3%) |
| Operating profit | ¥4,748 million (YoY -34.6%) |
| Ordinary income | ¥6,553 million (YoY -21.3%) |
| Profit attributable to owners of the parent | ¥4,177 million (YoY -33.1%) |
| Net income per share | ¥64.10 |
| Equity ratio | End of the current fiscal period 34.3 / End of previous period 36.6 |
| Total assets | ¥786,239 million |
| Net assets | ¥269,505 million |
| Cash flows from operating activities | ¥20,980 million |
| Cash flows from investing activities | ¥-2,498 million |
| Cash flows from financing activities | ¥-8,432 million |
| Cash and cash equivalents at end of period | ¥93,357 million |
| Full-year earnings forecast | Net Sales ¥1,601,000 million (YoY +3.1%) / Operating profit ¥14,800 million (YoY -10.9%) / Ordinary income ¥16,600 million (YoY -0.2%) / Net income ¥12,900 million (YoY -25.6%) |
| Annual Dividend Forecast | ¥165 → ¥180 |
| Segment revenue | Pharmaceutical wholesale business ¥781,345 million (YoY +5.7%), Dispensing pharmacy business ¥50,155 million (YoY +1.2%), Pharmaceutical manufacturing and marketing business ¥5,660 million (YoY -1.5%), Other related businesses ¥3,250 million (YoY -9.5%) |
| Segment profit | Pharmaceutical wholesale business ¥6,357 million (YoY -13.5%), Dispensing pharmacy business ¥166 million (YoY -72.3%), Pharmaceutical manufacturing and marketing business ¥109 million (YoY -8.6%), Other related businesses ¥165 million (YoY -65.3%) |
| Depreciation and amortization | ¥2,923 million |
| Impairment loss | No impairment loss recognized. The company stated that there were no applicable items for impairment losses on fixed assets by reporting segment. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥16 million, Gain on sale of investment securities ¥211 million, Gain on sale of shares of affiliates ¥185 million / Total extraordinary income ¥413 million / Extraordinary loss Loss on disposal of fixed assets ¥55 million, Loss on extinguishment of shares in a merger ¥573 million, Other ¥57 million / Total extraordinary losses ¥686 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 73,025,942 |
| Treasury Shares at Period-End | 7,660,199 |
| Factors Behind Changes in Business Performance | Across the market, sales exceeded the same period of the previous fiscal year, driven by growth in new drugs and other factors, with sales of anticancer drugs and specialty pharmaceuticals increasing. Meanwhile, profit declined due to lower demand for products related to COVID-19, higher procurement costs for pharmaceuticals, a decline in the number of prescriptions filled due to an increase in long-term prescriptions, delays in the launch of certain contract products, and surging material and raw material costs. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Across the market, demand for pharmaceuticals increased, driven in part by growth in new drugs, and sales of specialty pharmaceuticals and other products grew. Meanwhile, higher procurement costs for pharmaceuticals, a decline in the number of prescriptions filled due to an increase in long-term prescriptions, delays in the launch of certain contract products, and surging material and raw material costs put downward pressure on profit.